Pregabalin Follow-On Strategy a Winner for Pfizer

Introduction

The ongoing litigation surrounding the patent of Pfizer’s blockbuster anticonvulsant Neurontin (gabapentin) is expected to continue for at least another nine months. Unsurprisingly, Pfizer intends to stave off generic competition for as long as possible, at least until its follow-on product pregabalin can enter the CNS market and capture Neurontin’s share of revenues. 

Scope

Analysis of the reasons why Pfizer is developing pregabalin, through analysis of the blockbuster Neurontin 

Predicted outlook for pregabalin in three main markets it is expected to enter; epilepsy, anxiety, and neuropathic pain 

Analysis of recent clinical trials of current treatments and key late stage R&D products 

The pros and cons of off-label prescriptions are discussed, and forecasts are provided for Neurontin and pregabalin to 2010 

Report Highlights

So far, pregabalin has been evaluated for use in a number of CNS disorders ranging from epilepsy to generalized anxiety disorder, and offers a superior clinical profile to Neurontin. However, Datamonitor believes that an indication for neuropathic pain will provide the greatest return on investment for Pfizer. 

Datamonitor believes pregabalin will provide Pfizer with yet another blockbuster product. Sales are expected to cannibalize Neurontin following launch in 2003, as Pfizer minimizes generic erosion by convincing physicians to switch therapies. Datamonitor forecasts pregabalin to be worth over $2.82bn by 2010. 

Reasons to Purchase

Understand the reasoning behind the development of a follow-on drug to Neurontin 

Enhance your knowledge of the CNS markets targeted by pregabalin in terms of epidemiology, major competitors, and its future commercial outlook 

Gain an understanding of the pros and cons of off-label prescribing 

Optimize lifecycle management by understanding the strategies employed that will maintain Pfizer’s success in the anticonvulsant market 

Publisher: Datamonitor CNS Central Nervous System Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_CNS.html#a533